The changing face of post-transplant lymphoproliferative disease in the era of molecular EBV monitoring

Pediatric Transplantation

Volumn 14, Issue 4, 2010, Pages 504-511

  Kerkar, Nanda ^a   Morotti, Raffaella A ^a   Madan, Rebecca P ^a,b   Shneider, Benjamin ^a,c   Herold, Betsy C ^a,b   Dugan, Christina ^a   Miloh, Tamir ^a   Karabicak, Ilhan ^a   Strauchen, James A ^a   Emre, Sukru ^a,d  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^c CHILDREN S HOSPITAL OF PITTSBURGH   (United States)

^d YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Epstein Barr virus; Histology; Immunosuppression; Liver transplantation; Lymphoproliferative disease; Outcome

Indexed keywords

ADOLESCENT; AGE DISTRIBUTION; ARTICLE; CAUSE OF DEATH; CHILD; CHILDHOOD MORTALITY; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE COURSE; DISEASE DURATION; EPSTEIN BARR VIRUS INFECTION; FEMALE; GRAFT RECIPIENT; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INFANT; LIVER TRANSPLANTATION; LYMPHOPROLIFERATIVE DISEASE; MAJOR CLINICAL STUDY; MALE; PATIENT MONITORING; POSTOPERATIVE COMPLICATION; PRESCHOOL CHILD; RETROSPECTIVE STUDY; SCHOOL CHILD; TIME; VIRUS DIAGNOSIS; COMPARATIVE STUDY; EPSTEIN-BARR VIRUS INFECTIONS; LYMPHOPROLIFERATIVE DISORDERS; PATHOLOGY; POLYMERASE CHAIN REACTION; POSTOPERATIVE COMPLICATIONS; PREVALENCE; RISK FACTOR; UNITED STATES; VIROLOGY;

IMMUNOSUPPRESSIVE AGENT;

CHILD; CHILD, PRESCHOOL; EPSTEIN-BARR VIRUS INFECTIONS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LIVER TRANSPLANTATION; LYMPHOPROLIFERATIVE DISORDERS; POLYMERASE CHAIN REACTION; POSTOPERATIVE COMPLICATIONS; PREVALENCE; RETROSPECTIVE STUDIES; RISK FACTORS; TIME FACTORS; UNITED STATES;

EID: 77952262867     PISSN: 13973142     EISSN: 13993046     Source Type: Journal    
DOI: 10.1111/j.1399-3046.2009.01258.x     Document Type: Article

References (28)

1. D'Alessandro AM, Knechtle SJ, Chin LT, et al. Liver transplantation in pediatric patients: Twenty years of experience at the University of Wisconsin. Pediatr Transplant 2007 : 11 : 661 670.
2. Newell KA, Alonso EM, Whitington PF, et al. Posttransplant lymphoproliferative disease in pediatric liver transplantation. Interplay between primary Epstein-Barr virus infection and immunosuppression. Transplantation 1996 : 62 : 370 375.
3. Cacciarelli TV, Reyes J, Jaffe R, et al. Primary tacrolimus (FK506) therapy and the long-term risk of post-transplant lymphoproliferative disease in pediatric liver transplant recipients. Pediatr Transplant 2001 : 5 : 359 364.
4. Thorley-Lawson DA. Epstein-Barr virus: Exploiting the immune system. Nat Rev Immunol 2001 : 1 : 75 82.
5. Savoie A, Perpete C, Carpentier L, et al. Direct correlation between the load of Epstein-Barr virus-infected lymphocytes in the peripheral blood of pediatric transplant patients and risk of lymphoproliferative disease. Blood 1994 : 83 : 2715 2722.
6. Uemura T, Ikegami T, Sanchez EQ, et al. Late acute rejection after liver transplantation impacts patient survival. Clin Transplant 2008 : 22 : 316 323.
7. Harris NL, Jaffe ES, Diebold J, et al. The World Health Organization classification of neoplastic diseases of the haematopoietic and lymphoid tissues: Report of the Clinical Advisory Committee Meeting, Airlie House, Virginia, November 1997. Histopathology 2000 : 36 : 69 86.
8. Macsween RNM, Burt AD, Portmann BC, et al. Pathology of the liver. In : Hubscher SG, Portmann BC, eds. Transplantation Pathology.
9. Starzl TE, Nalesnik MA, Porter KA, et al. Reversibility of lymphomas and lymphoproliferative lesions developing under cyclosporin-steroid therapy. Lancet 1984 : 1 : 583 587.
10. McDiarmid SV, Jordan S, Kim GS, et al. Prevention and preemptive therapy of postransplant lymphoproliferative disease in pediatric liver recipients. Transplantation 1998 : 66 : 1604 1611.
11. Green M, Michaels MG, Katz BZ, et al. CMV-IVIG for prevention of Epstein Barr virus disease and posttransplant lymphoproliferative disease in pediatric liver transplant recipients. Am J Transplant 2006 : 6 : 1906 1912.
12. Rowe DT, Webber S, Schauer EM, et al. Epstein-Barr virus load monitoring: Its role in the prevention and management of post-transplant lymphoproliferative disease. Transpl Infect Dis 2001 : 3 : 79 87.
13. Rowe DT, Qu L, Reyes J, et al. Use of quantitative competitive PCR to measure Epstein-Barr virus genome load in the peripheral blood of pediatric transplant patients with lymphoproliferative disorders. J Clin Microbiol 1997 : 35 : 1612 1615.
14. Gulley ML, Fan H, Elmore SH. Validation of Roche LightCycler Epstein-Barr virus quantification reagents in a clinical laboratory setting. J Mol Diagn 2006 : 8 : 589 597.
15. Harris NL, Swerdlow SH, Frizzera G, et al. Post transplant lymphoproliferative disease. In : Jaffe EJ, Harris NL, Stein H, et al., eds. The World Health Classification of Tumors.
16. Feng T, Ye F, Wu J, et al. Effect of Epstein-Barr virus sequence variation on performance of the Roche real-time LightCycler PCR assay. J Clin Microbiol 2008 : 46 : 2463 2465.
17. Feng T, Ye F, Wu J, et al. The effect of EBV sequence variation on the performance of a Roche real-time Lightcycler PCR assay. J Clin Microbiol 2008 : 46 : 2463 2465.
18. Kerkar N, Hadzic N, Davies ET, et al. De-novo autoimmune hepatitis after liver transplantation. Lancet 1998 : 351 : 409 413.
19. Jain AB, Marcos A, Pokharna R, et al. Rituximab (chimeric anti-CD20 antibody) for posttransplant lymphoproliferative disorder after solid organ transplantation in adults: Long-term experience from a single center. Transplantation 2005 : 80 : 1692 1698.
20. Davis CL, Wood BL, Sabath DE, et al. Interferon-alpha treatment of posttransplant lymphoproliferative disorder in recipients of solid organ transplants. Transplantation 1998 : 66 : 1770 1779.
21. Lee TC, Savoldo B, Rooney CM, et al. Quantitative EBV viral loads and immunosuppression alterations can decrease PTLD incidence in pediatric liver transplant recipients. Am J Transplant 2005 : 5 : 2222 2228.
22. Stevens SJ, Verschuuren EA, Pronk I, et al. Frequent monitoring of Epstein-Barr virus DNA load in unfractionated whole blood is essential for early detection of posttransplant lymphoproliferative disease in high-risk patients. Blood 2001 : 97 : 1165 1171.
23. Dufour JF, Fey MF. What is the current treatment of PTLD after liver transplantation? J Hepatol 2006 : 44 : 23 26.
24. Choquet S, Leblond V, Herbrecht R, et al. Efficacy and safety of rituximab in B-cell post-transplantation lymphoproliferative disorders: Results of a prospective multicenter phase 2 study. Blood 2006 : 107 : 3053 3057.
25. Rooney CM, Smith CA, Ng CY, et al. Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients. Blood 1998 : 92 : 1549 1555.
26. Oertel SH, Verschuuren E, Reinke P, et al. Effect of anti-CD 20 antibody rituximab in patients with post-transplant lymphoproliferative disorder (PTLD). Am J Transplant 2005 : 5 : 2901 2906.
27. Bingler MA, Feingold B, Miller SA, et al. Chronic high Epstein-Barr viral load state and risk for late-onset posttransplant lymphoproliferative disease/lymphoma in children. Am J Transplant 2008 : 8 : 442 445.
28. Kogan-Liberman D, Burroughs M, Emre S, et al. The role of quantitative Epstein-Barr virus polymerase chain reaction and preemptive immunosuppression reduction in pediatric liver transplantation: A preliminary experience. J Pediatr Gastroenterol Nutr 2001 : 33 : 445 449.